Egrifta (Tesamorelin) MMA / Combat Sports Protocol

What Is Tesamorelin and Why Do Combat Athletes Use It?

Tesamorelin is a 44-amino-acid synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). The FDA approved it in 2010 under the brand name Egrifta for HIV-associated lipodystrophy, and an improved formulation (Egrifta SV) received approval in 2019 [1]. Its mechanism is distinct from exogenous human growth hormone (HGH): rather than flooding the body with a fixed GH dose, it stimulates the pituitary to release GH in physiological pulses, preserving negative feedback and reducing the risk of sustained supraphysiologic IGF-1 levels [2].

Why MMA Athletes Are Interested

Combat sports generate a uniquely demanding physiological environment. Fighters absorb repeated head impacts, train through soft-tissue injuries, and often need to strip body fat for weight class without losing lean mass. GH and IGF-1 both support collagen synthesis, satellite cell activation for muscle repair, and central nervous system health after injury [3]. Tesamorelin raises IGF-1 by roughly 50 to 75 ng/mL above baseline in clinical populations, and that IGF-1 elevation is the primary driver of its tissue-repair and neuroprotective interest [4].

Regulatory Reality

WADA's 2024 Prohibited List explicitly bans GHRH analogues both in-competition and out-of-competition under S2 (Peptide Hormones and Related Substances) [5]. Any sanctioned combat athlete reading this should treat the following protocol information as educational and consult their sport's anti-doping authority before use.

Clinical Evidence Base: What the Data Actually Show

Before any dosing protocol makes sense, the evidence level for each use case needs to be clear. Tesamorelin's data ranges from rigorous Phase 3 RCTs to small observational studies and animal mechanistic work.

Body Composition (Highest Evidence Level: Phase 3 RCT)

The LIPO-010 trial (N=816) demonstrated that tesamorelin 2 mg daily for 26 weeks reduced visceral adipose tissue by a mean of 15.2% versus 1.5% in placebo (P<0.001) without significant changes in subcutaneous fat or lean mass [6]. A 52-week extension confirmed durability. The visceral fat reduction is mediated through GH-stimulated lipolysis and is meaningful for fighters managing weight class. Lean-mass preservation in these trials was statistically significant compared to placebo, though absolute gains were modest (approximately 1.3 kg) [6].

Soft-Tissue and Musculoskeletal Repair (Moderate Evidence: RCT and Animal Data)

IGF-1, the downstream effector of tesamorelin-stimulated GH, accelerates type-1 collagen synthesis and tendon fibroblast proliferation. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=61, healthy older adults) showed that 6 months of GHRH analogue therapy increased thigh muscle volume measured by MRI and improved physical performance scores versus placebo [7]. Animal data show IGF-1 promotes rotator cuff and Achilles tendon repair after surgical injury, though direct RCT data in humans with acute sports injuries are lacking [3].

Neuroprotection After Concussion (Emerging Evidence: Observational and Animal RCT)

This is the use case that draws the most clinical curiosity in combat sports medicine. Repeated subconcussive impacts and frank concussions are endemic in MMA, boxing, and Muay Thai. GH deficiency is documented in 15 to 20% of moderate-to-severe TBI patients and correlates with worse cognitive and mood outcomes [8]. A 2012 observational study (N=37, post-TBI patients) found that GH replacement improved cognitive function, fatigue, and quality-of-life scores over 12 months [9]. Tesamorelin, by stimulating endogenous GH rather than replacing it exogenously, may restore the physiological pulsatility that supports neuronal IGF-1 signaling in the hippocampus and prefrontal cortex.

A 2023 randomized, double-blind, placebo-controlled trial in military veterans with Gulf War illness (N=152) tested tesamorelin 1 mg/day for 12 months. Tesamorelin-treated subjects showed significant improvement on a composite cognitive score (P=0.02) and on episodic memory sub-scores [10]. This is the strongest human clinical evidence connecting tesamorelin specifically to cognitive benefit, though the population (veterans with GWI) differs from healthy athletes absorbing acute impacts.

The HealthRX Combat Sports Tesamorelin Protocol

The following protocol is derived from FDA-approved dosing parameters, the clinical trial data cited above, and off-label practitioner frameworks reviewed by the HealthRX medical team. It is not a prescription. All use requires physician supervision, baseline labs, and ongoing monitoring.

Phase 1: Baseline Assessment (Weeks -2 to 0)

Before the first injection, obtain the following labs:

• Fasting IGF-1 (establishes your pre-treatment baseline; target reference range for athletes is generally 150 to 350 ng/mL depending on age)
• Fasting glucose and HbA1c (tesamorelin can induce glucose intolerance; the LIPO-010 trial showed a 2.3% incidence of new-onset glucose intolerance versus 1.0% placebo) [6]
• Comprehensive metabolic panel (liver and kidney function)
• Lipid panel (GH elevation modestly reduces LDL and triglycerides)
• PSA (males over 40)

A review of recent imaging for any active soft-tissue injuries is advisable. Document any post-concussion symptoms using a validated scale such as the Sport Concussion Assessment Tool (SCAT6) if neuroprotective use is the primary goal.

Phase 2: Induction Block (Weeks 1 to 8)

Dose: 1 mg subcutaneous injection once daily.

Injection site: Abdomen, rotating quadrants. The FDA label specifies subcutaneous abdominal injection [1]. Avoid injecting into scar tissue or areas with active bruising from training.

Timing: Bedtime administration capitalizes on the circadian GH peak that naturally occurs during slow-wave sleep. Injecting 30 to 60 minutes before sleep amplifies this pulse rather than overriding it.

Reconstitution (lyophilized powder formulations): Use bacteriostatic water per manufacturer instructions. Egrifta SV uses a sterile water diluent provided in a dual-chamber prefilled syringe, simplifying preparation [1].

What to expect in weeks 1 to 4: Sleep quality improvements are often reported first. Some athletes notice reduced soreness within 2 to 3 weeks as GH-mediated anti-inflammatory signaling increases. Body composition changes are not visible in this window.

What to expect in weeks 5 to 8: Noticeable improvements in recovery speed between training sessions. Fighters on aggressive weight cuts may notice visceral fat reduction beginning around week 6. Cognitive clarity and mood stabilization are reported anecdotally in the post-concussion use case, consistent with the 12-week cognitive data from the veterans trial [10].

Phase 3: Maintenance Block (Weeks 9 to 16)

Dose: Some physicians increase to 2 mg daily at week 9 if IGF-1 has not reached the mid-normal range for the athlete's age-adjusted reference interval and if fasting glucose remains below 100 mg/dL.

The LIPO-010 trial used 2 mg/day and confirmed visceral fat reduction was dose-dependent [6]. Body composition benefits and soft-tissue support likely follow a similar dose-response curve, though no head-to-head 1 mg vs. 2 mg RCT in athletes exists.

Mid-cycle labs at week 8 to 10:

• Fasting IGF-1 (target: 100 to 200 ng/mL above baseline, not exceeding the upper limit of the age-adjusted normal range)
• Fasting glucose
• HbA1c (if baseline was borderline)

If IGF-1 is above the upper limit of normal for age, reduce dose to 1 mg or pause the cycle.

Phase 4: Off-Cycle (Weeks 17 to 24)

A minimum 4-week off period allows the pituitary to reset. Practitioners commonly use an 8-week off interval to match the 8-week on-cycle length. During the off period, endogenous GH pulsatility returns to baseline within days because tesamorelin's half-life is approximately 26 to 38 minutes [2].

Labs at end of off-cycle confirm IGF-1 return to pre-treatment baseline before initiating a second block.

Dosing by Use Case: A Structured Summary

| Use Case | Starting Dose | Maintenance Dose | Cycle Length | Key Monitoring | |---|---|---|---|---| | Visceral fat / weight class | 2 mg/day | 2 mg/day | 12 to 26 weeks | IGF-1, glucose | | Soft-tissue repair acceleration | 1 mg/day | 1 to 2 mg/day | 8 to 12 weeks | IGF-1, HbA1c | | Post-concussion neuroprotection | 1 mg/day | 1 mg/day | 12 months (per veterans RCT [10]) | IGF-1, fasting glucose, cognitive assessment | | General recovery optimization | 1 mg/day | 1 mg/day | 8 to 16 weeks | IGF-1, glucose |

Tesamorelin Timing Around Training and Fight Camp

Training Days

Bedtime injection is preferred on all days, including heavy sparring sessions. Post-training GH release is already elevated from acute exercise; administering tesamorelin in the morning on a training day would create GH peaks that may partially overlap with exercise-induced GH, producing no additional advantage and potentially increasing IGF-1 overshoot.

Fight Week and Weight Cuts

Tesamorelin should be paused 48 to 72 hours before a water cut if severe dehydration is planned. GH stimulates renal water retention through IGF-1, and extreme dehydration combined with GH elevation may cause electrolyte shifts. Resume after weigh-in.

Post-Fight Recovery Window

The 72-hour window immediately after a fight, especially one involving significant strikes to the head or body, represents the highest-value recovery period. Some clinicians advocate continuing tesamorelin through fight week at 1 mg/day precisely because the GH pulse supports glymphatic clearance (the brain's waste-removal system during sleep) [11]. Animal data show that GH receptor signaling in astrocytes supports aquaporin-4 function, a protein central to glymphatic flow [11]. This is mechanistic evidence, not a human RCT finding.

Side Effects and Contraindications Specific to Athletes

Glucose Dysregulation

The most clinically significant risk for athletes is glucose intolerance. GH is counter-regulatory to insulin. In the LIPO-010 RCT, tesamorelin increased fasting glucose by a mean of 3.2 mg/dL at 26 weeks [6]. Athletes consuming high-carbohydrate diets should monitor fasting glucose monthly. Those with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) require more frequent monitoring and may need dose reduction.

Fluid Retention

Peripheral edema and joint pain from fluid retention occur in roughly 6% of users at 2 mg/day [1]. This is dose-dependent and typically resolves with dose reduction. Fighters who misinterpret water retention as lean mass gain may be disappointed on the scale.

Injection Site Reactions

Erythema and pruritus at the injection site occur in approximately 5% of patients in clinical trials [1]. Rotating the injection site through four abdominal quadrants minimizes this.

Absolute Contraindications

• Active or suspected malignancy (GH and IGF-1 are growth signals; cancer cells may exploit them)
• Pregnancy or breastfeeding
• Hypersensitivity to tesamorelin, its analogue components, or mannitol (the excipient in some formulations)
• Pituitary tumor or hypothalamic disease affecting GH axis

Comparing Tesamorelin to Other Peptides Used in Combat Sports

Tesamorelin vs. CJC-1295 / Ipamorelin

CJC-1295 (a GHRH analogue) combined with Ipamorelin (a GHRP) is popular in performance circles, but neither has FDA approval and neither has been evaluated in an RCT of comparable size to the LIPO-010 trial. Tesamorelin's clinical data package is substantially larger, giving prescribing physicians more guidance on expected IGF-1 responses, glucose effects, and cycle safety. The trade-off is cost: compounded CJC-1295/Ipamorelin is cheaper than brand-name Egrifta.

Tesamorelin vs. Sermorelin

Sermorelin is another GHRH analogue, shorter in sequence (29 amino acids vs. 44 for tesamorelin) and generally producing a smaller IGF-1 response. A head-to-head comparison study found tesamorelin produced approximately twice the IGF-1 elevation of sermorelin at equivalent molar doses [4]. For athletes seeking meaningful GH stimulation in an 8 to 16 week cycle, tesamorelin's stronger IGF-1 signal is an advantage.

Tesamorelin vs. BPC-157

BPC-157 is a synthetic peptide derived from gastric juice, used primarily for local tendon and gut repair. Its mechanism is entirely different (primarily local cytoprotection rather than systemic GH axis stimulation) and the evidence base is limited to animal studies [12]. Fighters sometimes stack BPC-157 with tesamorelin for localized injury repair plus systemic recovery optimization, though no RCT data support this combination.

What Physicians Look for When Prescribing Off-Label

The HealthRX medical team, when evaluating a fighter for tesamorelin use, considers the following clinical picture:

Favorable candidates:

• Documented GH deficiency or low-normal IGF-1 (below 150 ng/mL for age 25 to 40)
• History of multiple concussions with documented post-concussive syndrome
• Recurrent soft-tissue injuries (ligament sprains, muscle tears) with slow healing
• Overtraining syndrome with elevated cortisol and suppressed GH axis

Unfavorable candidates:

• IGF-1 already above 300 ng/mL (further stimulation carries diminishing returns and increased side-effect risk)
• Pre-diabetes or metabolic syndrome (glucose risk outweighs benefit without very careful monitoring)
• Active WADA-tested athlete (banned substance; career risk is absolute)

The Endocrine Society's clinical practice guideline on adult GH deficiency states: "GH replacement therapy is indicated when the diagnosis of GH deficiency is confirmed biochemically and symptoms are present that are likely to respond to treatment." [13] Fighters using tesamorelin without a confirmed deficiency are using it in a gray zone that is off-label by definition.

Expected Timeline of Outcomes

| Timeframe | Reported Outcomes | Evidence Level | |---|---|---| | Weeks 1 to 2 | Improved sleep depth, reduced morning soreness | Anecdotal / mechanistic | | Weeks 3 to 6 | Faster soft-tissue recovery between sessions, early lean mass preservation | Observational | | Weeks 6 to 12 | Measurable visceral fat reduction (10 to 15%), IGF-1 elevation confirmed on labs | Phase 3 RCT [6] | | Months 3 to 12 | Cognitive improvement in post-concussive population | Randomized trial (GWI veterans) [10] | | Off-cycle (weeks 1 to 4) | IGF-1 returns to baseline; GH pulsatility normalized within days | Pharmacokinetic data [2] |

Stacking Tesamorelin: What Physicians Consider

Some combat sports physicians consider tesamorelin within a broader recovery protocol. Common co-prescriptions in supervised clinical settings include:

• Testosterone replacement therapy (TRT): GH and testosterone are synergistic for lean mass; each works through distinct receptor pathways. Monitoring IGF-1 and hematocrit separately is mandatory.
• Melatonin 0.5 to 3 mg at bedtime: Supports the same slow-wave sleep window targeted by bedtime tesamorelin dosing without pharmacological interaction.
• Creatine monohydrate 3 to 5 g/day: Supports satellite cell-driven muscle repair through a mechanism independent of the GH axis; no interaction with tesamorelin pharmacology [3].

No RCT data exist for any of these combinations in athletes. Each addition requires individual risk-benefit assessment.